



*Powering Life Science Partnering & Mentoring*

## **EPPIC 2010 Annual Conference**

### **Emerging Trends and Opportunities in Life Sciences**

The EPPIC annual life science conference combines networking, mentoring and keynote lectures and panel discussions on current topics. The annual conference also focuses on promoting cross-border (US-India) collaborations and attracts multiple individuals and organizations interested in leveraging potential synergies. This year's panels -- personalized medicine, bio-similars, medical devices and life science funding will give attendees a good grasp on the latest trends in industry. For the first time, the conference will host a speed networking session and a career workshop. The conference brings budding and seasoned entrepreneurs, senior executives, scientists, venture capitalists and legal experts, together to tell their stories and will attract potential partners, employers and investors.

### **Agenda**

7.30 - 8.00 am Registration and Refreshments

8.00 - 8.30 am **Welcome: *EPPIC 2010 and Beyond***; Jagath Reddy Junutula, EPPIC

President, Scientist/Group leader, Genentech

**Abstract:** EPPIC President plans to unveil on how EPPIC is taking on new initiatives to build networking, collaborations among life science professionals, to foster future entrepreneurs and scientists and to promote US-India life science synergy.

8.30 - 9.15 am **Plenary Seminar 1: *Academia, Biotech and Pharma: New Models for Drug Discovery and Development***; Corey Goodman, Co-Founder & MD, venBio LLC, former President Pfizer-BBC

**Abstract:** The potential for making breakthrough medicines to help solve major unmet medical needs have never been so high. If the tools and technologies and targets for drug discovery are greater than ever, then why are there so few new drugs? One answer is that we need new models for drug discovery and development that build bridges from academia to biotech to pharma, harnessing the best from all three worlds. In this talk, we will consider what is broken, and how to fix it. We need all three legs of the stool – academia, biotech, and pharma – working together in new collaborative models if we are going to deliver on the promise of bringing important new medicines forward for human health.

9.15 - 9.45 am **Keynote Address 1: *Personalized Medicine: from traditional clinical diagnosis to companion diagnostics***; Sara Kenkare-Mitra, Vice President, Genentech

**Abstract:** This seminar will focus on the role of diagnostics in clinical medicine from the past to the present and the increasing interest and potential of newer technologies in selecting the right patients that will benefit from specific drugs or in whom the drug will be safe. Examples will be provided.

9.45 - 10.45 am **Panel 1: *Personalized / Targeted Medicine***

**Moderator:** Meeta Patnaik (Managing Director, Transtek Clinical Systems); Paul Billings (CSO, El Camino Real Hospital Genomic Medicine Institute); Dave Johnson (COO & Sr. VP, Gene Security Network); Steve Rosenberg (CSO, CardioDx); John J. Sninsky (VP, Celera Corporation); Vance Vanier (CMO, Navigenics)

**Panel Description: "Personalized Medicine"** has been described as the application of genomic and molecular data to better target the delivery of healthcare, facilitate the discovery and clinical testing of new products, and help determine a person's predisposition to a particular disease or response to a drug. Recent developments in a number of molecular profiling technologies, including proteomic profiling, metabolomic analysis, genomic/genetic testing as well as imaging and bioinformatic technologies allow the development of personalized and predictive medicine, which integrates this diagnostic information with proactive, personalized and preventive medicine. It is hoped that personalized medicine will allow health care providers to focus their attention on factors specific to an individual patient to provide individualized care. This panel will focus on the challenges faced in developing and launching these tools successfully in the global landscape, including regulatory and reimbursement hurdles as well as validation and deployment of these technologies in drug development and the clinic.

10.45 – 11.15 am **Session 1: *Speed Networking***

**Session Description:** An opportunity to meet over 100 attendees by 3 min quick introductions with a group of three attendees and also in a group setting. Please bring ~150 business cards.

11.15 - 12.00 noon **Session 2: *Featured Presentations***

11.15 – 11.30 am **LamdaGen Corporation: *Proprietary optical biosensors - Bringing Nanotechnology to Biotechnology***; Nicholas Virca, COO, LamdaGen

**Abstract:** This presentation highlights LamdaGen 's unique proprietary optical biosensor technology and they also showcase live on site demonstrations during exhibit hours describing their unique applications. This technology is used to characterize diverse biomolecular interactions between targets such as DNA, RNA, proteins, peptides and low molecular weight compounds.

11.30 – 11.45 am **Nature Biotechnology: *its initiative to build a biotech community***; Brady Huggett, Business Editor, Nature Biotechnology

**Abstract:** This talk will focus on the *Nature Biotechnology's* Bioentrepreneur section, the recently launched Meet the Author discussion series, and *Nature Biotechnology's* efforts to build a community of like-minded researchers hoping to commercialize their efforts on the bench.

11.45 – 12.00 noon **InnerTrek™: *Make the Right Waves: An introduction to effective communication***; Bob Figari, founder, InnerTrek™

**Abstract:** This talk will feature an introduction to what counts the most in making one-on-one communications and large group presentations effective at all company levels.

12.00 – 1.00 pm **Lunch Break**

1.00 - 1.30 pm **Keynote Address 2: *Comparability for Biologics: Scientific and Regulatory Trends***; Wassim Nashebeh, Sr. Director, Genentech

**Abstract:** This seminar will highlight recombinant biologics therapeutics: what makes them different from a CMC perspective? Technical and regulatory evolution of comparability for biologics and current thoughts on comparability and Biosimilars.

### 1.30 - 2.30 pm **Panel 2: Current Trends in Biosimilars**

**Moderator:** Anie Roche (VP, Adamas Pharmaceuticals); Bruce Mackler (Consultant on FDA matters); Sean Meduck (Sr. Mgr, Genentech); Arun Nataraj (Assoc. Dir., Lonza); Stan Yakatan (Managing Partner, Katan Associates)

**Panel Description:** Biologics have opened the floodgates for innovative treatment options and made remarkable changes in the practice of medicine over the last 2 decades. Manufacturing of these drugs involves living cells, creates challenges to establish chemical and biological, therapeutic equivalence of purified products. US policymakers and the US FDA are working to create a path for approval of Biosimilars to make these drugs more affordable. This panel will discuss and brainstorm the current trends in Biosimilars.

### 2.30 - 3.00 pm **Keynote Address 3: Exportation of the Medical Device Complex;** Tom J. Fogarty, President, Fogarty Eng. & Institute of Innovation

**Abstract:** In the US, there has been increasing regulations and decreasing reimbursement for the entire medical industry. Increasing regulation, complicated clinical trials in conjunction with FDA issues, significantly impact the efficiency and cost of clinical trials. This has adverse consequences on our ability to bring new technology to our patients. The response of the medical industrial complex is to do as much as possible offshore. I.e. manufacturing, clinical trials, etc. Our patients understand the advantages of improved technology and are receiving it at a reduced cost offshore.

### 3.00 – 4.00 pm **Panel 3: NEW OPPORTUNITIES IN MEDICAL DEVICES**

**Moderator:** Kern Bhugra (CEO, Tibion Bionic Tech.); Kenneth R. Allen (Patent Lawyer, Townsend, Townsend & Crew LLP); Mudit Jain (VC, Synergy Life Science Partners); S. Nandakumar (CEO, Perfint); David Wood (President & CEO, Spinal Modulation)

**Panel Description:** The medical device field has been a fertile area for inventions and proven to be a great business opportunity for both start-ups and established companies. Technology advancement in the field has improved the standard of care across a spectrum of indications for patients and clinicians on a global scale. Kern Bhugra is a successful entrepreneur in the medical device industry and will give a tour of this vibrant world. The panelists will summarize their views on the emerging opportunities and future of the medical device field from the perspective of investors, entrepreneurs, and legal experts.

### 4.00 – 4.30 pm **Session 3: Career Workshop & Exhibit break**

**Key activities:** A demo by LamdaGen, An information booth on “improving health of South Asians” by Dr. Ron Sinha, Palo Alto Medical Foundation; A presentation by Bob Figari (4.10 – 4.30 pm) on “Make the Right Career Waves: An introduction to effective career communication” and a Career Workshop by Holly Butler and team in parallel with Panel 4 and will continue till 5.30 pm.

### 4.30 – 5.30 pm **Panel 4: THE FUTURE OF LIFE SCIENCE FUNDING**

**Moderator:** Ravi Kiron (Managing Director, Adjuvant Global Advisors, LLC); Vijay Chandru (CEO, Strand Life Sciences & President, ABLE, India); Andrew Chung (VC, Light Speed); Anula Jayasuriya (VC, Evolve India Life Science Fund); Nagesh Mhatre (Partner, The Angels Forum - Halo Fund); Yatin Mundkur (Partner, Artiman Ventures)

**Panel Description:** Investments in all aspects of life sciences have started their slow but sure return to previous support levels. The lack of liquidity in capital markets and the hesitancy to engage in the risk profile of emerging companies made 2009 as a year to forget as it relates to life science funding. In addition to the usual VC funds, there are emerging corporate venture funds, private equity investments and funding from non-traditional sources that includes India/China and other Asian nations, interested to capitalize on the US biotech industry opportunities. This panel will address the future of funding in life sciences that will provide a good ROI for the investors.

### 5.30 – 6.15 pm **Plenary Seminar 2: Accelerating innovation on a platform of affordability - the new mathematics of global healthcare,** Kiran Mazumdar Shaw, Chairman and Managing Director, Biocon Ltd.

**Abstract:** BioCon is India's most successful Biotech company. In 2006 BioCon launched India's first NCE Monoclonal Antibody cancer drug, BIOMAb. BioCon has also established several marketing and R&D partnerships with companies around the globe. Under the leadership of Kiran Mazumdar, BioCon is well on its way to becoming a leading global pharma company.

### 6.15 – 6.30 pm **EPPIC Awards & Felicitations**

### 6.30 – 7.00 pm **Evening Reception:** Cocktails and light refreshments